Stocks of Vir Biotechnology Inc (NASDAQ:VIR) traded higher last session on Wall Street, down -0.37% to $5.41.
VIR stock price is now 2.71% away from the 50-day moving average and -26.42% away from the 200-day moving average. The market capitalization of the company currently stands at $747.87M.
With the price target reduced from $23 to $9, JP Morgan Downgraded its rating from Overweight to Neutral for Vir Biotechnology Inc (NASDAQ: VIR). On September 08, 2023, BofA Securities Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $23 to quote $14, while ‘JP Morgan’ rates the stock as ‘Overweight’
In other news, SATO VICKI L, Director sold 22,000 shares of the company’s stock on Jul 01 ’25. The stock was sold for $112,207 at an average price of $5.10. Upon completion of the transaction, the Director now directly owns 1,298,391 shares in the company, valued at $7.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01 ’25, Director VICKI LEE SATO bought 66,000 shares of the business’s stock. A total of $332,640 was incurred on buying the stock at an average price of $5.04. A total of 35.56% of the company’s stock is owned by insiders.
During the past 12 months, Vir Biotechnology Inc has had a low of $4.32 and a high of $14.45. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 6.79, and a quick ratio of 6.79. The fifty day moving average price for VIR is $5.2675 and a two-hundred day moving average price translates $7.353 for the stock.
The latest earnings results from Vir Biotechnology Inc (NASDAQ: VIR) was released for 2025-03-31. The net profit margin was -2769.04% and return on equity was -44.59% for VIR. The company reported revenue of $3.03 million for the quarter, compared to $56.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.62 percent.
